John Fesko Sells 781 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 781 shares of the stock in a transaction on Monday, October 27th. The shares were sold at an average price of $192.32, for a total value of $150,201.92. Following the completion of the transaction, the insider directly owned 151,627 shares in the company, valued at approximately $29,160,904.64. This trade represents a 0.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

John Fesko also recently made the following trade(s):

• On Tuesday, October 28th, John Fesko sold 928 shares of Natera stock. The stock was sold at an average price of $191.46, for a total value of $177,674.88.
• On Tuesday, October 21st, John Fesko sold 339 shares of Natera stock. The shares were sold at an average price of $187.95, for a total value of $63,715.05.
• On Thursday, August 14th, John Fesko sold 678 shares of Natera stock. The shares were sold at an average price of $155.46, for a total value of $105,401.88.

Natera Trading Up 0.2%

Shares of NTRA opened at $193.22 on Friday. The stock has a market cap of $26.52 billion, a P/E ratio of -101.16 and a beta of 1.74. Natera, Inc. has a 1 year low of $120.67 and a 1 year high of $198.99. The stock’s 50-day moving average price is $173.77 and its two-hundred day moving average price is $161.57.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business’s revenue was up 32.2% compared to the same quarter last year. During the same period last year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on NTRA. BNP Paribas upgraded shares of Natera to a “hold” rating and set a $172.00 target price on the stock in a report on Monday. Cowen restated a “buy” rating on shares of Natera in a research report on Friday, August 8th. Morgan Stanley reiterated an “overweight” rating and set a $195.00 target price on shares of Natera in a report on Sunday, August 10th. Zacks Research cut Natera from a “hold” rating to a “strong sell” rating in a research note on Monday, October 20th. Finally, BNP Paribas Exane raised Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price target on the stock in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $194.89.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Bank of Jackson Hole Trust acquired a new stake in Natera in the 1st quarter valued at approximately $29,000. TCTC Holdings LLC boosted its position in Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after acquiring an additional 124 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after acquiring an additional 106 shares in the last quarter. Hilltop National Bank acquired a new stake in shares of Natera in the second quarter valued at approximately $33,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new stake in shares of Natera in the second quarter worth $36,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.